United Kingdom Influenza Treatment Market Size, Share & Trends Analysis Report By Product (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy) and Forecasts, 2026-2034

United Kingdom Influenza Treatment Market Size

The United Kingdom influenza treatment market size was valued at USD 842 million in 2025 and is projected to grow from USD 913.57 million in 2026 to reach USD 1754.61 million by 2034, growing at a CAGR of 8.50% during the forecast period 2026–2034.

The market growth is primarily driven by the rising incidence of influenza outbreaks, increased government focus on flu prevention and treatment, and the growing demand for antiviral treatments, particularly during winter. The UK's healthcare infrastructure, combined with its advanced medical research capabilities, creates a favorable environment for market growth.

Drug Types Insights

Locally Acting Antiviral Agents dominate the drug type segment and are expected to grow at a CAGR of 3.3% over the forecast period. Locally acting antivirals, which target the influenza virus directly at the site of infection, offer significant advantages over traditional antiviral treatments, including reduced side effects and faster recovery. This category includes drugs such as baloxavir marboxil, which is gaining popularity due to its effectiveness and reduced pill burden. With increasing adoption in hospitals and clinics, locally acting antivirals are expected to dominate the market in the coming years. The preference for targeted treatments and the growing demand for flu-specific medications support the continued expansion of this segment.

Request Customizationto receive a tailored report.

End User Insights

Hospitals and clinics remain the largest end-users of influenza treatments in the United Kingdom, with a projected growth rate of 3.6% during the forecast period. The country’s healthcare system is well-equipped to manage influenza cases, with hospitals as the primary sites for flu treatments, especially during peak flu seasons. NHS hospitals are critical in managing flu-related hospitalizations, particularly treating high-risk groups such as the elderly. The increasing flu-related hospital admissions during seasonal outbreaks will continue to drive demand for antiviral treatments in these healthcare settings, ensuring steady growth for this segment.

Speak to an Analystto discuss market opportunities.

United Kingdom Influenza Treatment Market Regional Insights

The market is characterized by the country’s robust healthcare system, increasing influenza outbreaks, and a focus on prevention and treatment.

• London plays a central role in the influenza treatment market as the UK's capital city. With a large population and numerous healthcare facilities, including prestigious institutions like St. Thomas' Hospital and King's College Hospital, the city is at the forefront of treatment. London’s dense population and frequent outbreaks during flu season contribute significantly to the demand for antiviral medications. Additionally, London’s access to cutting-edge medical research and pharmaceutical companies further strengthens its position as a key market for influenza treatments.
• Manchester, one of the largest cities in the UK, also sees a high demand for influenza treatments, particularly in its extensive hospital network, including the Manchester Royal Infirmary. The city's healthcare infrastructure ensures that the population receives timely treatment during flu season. Manchester’s commitment to public health initiatives, such as flu vaccination programs, supports the growing demand for antiviral drugs. The city's aging population further amplifies the need for effective flu treatments.
• Birmingham, the second-largest city in the UK, has a significant presence of healthcare facilities like the Queen Elizabeth Hospital, which plays a crucial role in influenza treatment. Birmingham’s diverse population and many elderly residents make it a key market for antiviral drugs. The city's hospitals and clinics are central to providing treatment during outbreaks, and the ongoing investments in healthcare infrastructure ensure that antiviral medications are readily accessible.
• Liverpool, with its extensive healthcare network and large student population, also experiences high seasonal flu rates. Hospitals such as the Royal Liverpool University Hospital are integral to providing treatments. The city’s demographic, with a mix of young adults and elderly citizens, creates varied demands for antiviral therapies. The increase in flu-related hospitalizations during winter ensures that Liverpool remains a critical region for the influenza treatment market.
• Edinburgh, the capital city of Scotland, experiences seasonal flu outbreaks, particularly among its elderly population. The city’s healthcare system, led by institutions such as the Western General Hospital, is essential for influenza care. Edinburgh’s high vaccination rates and health awareness initiatives also contribute to the demand for effective antiviral treatments. The city’s role as a significant healthcare and research hub further supports the market's growth.

List of Key and Emerging Players in United Kingdom Influenza Treatment Market